Physician profile
Michael J Dittman
NPI 1033176698
$3,713.47
in general payments reported to CMS, 2019-2025
12 companies · $522 in 2025
The $522 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $126 · 2021: $298 · 2022: $134 · 2023: $91.59 · 2024: $2,301 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Travel and Lodging: $1,297 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.91 |
| Travel and Lodging | $1,296.62 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,362.42 | 2019-2025 | Precision7, Total30, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $562.23 | 2024-2025 | Xdemvy |
| Coopervision INC. | $189.57 | 2020-2025 | Misight Contact Lens |
| Allergan, INC. | $161.50 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $133.72 | 2024-2025 | Vyzulta, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.11 | 2019-2020 | |
| Abbvie INC. | $76.60 | 2022-2023 | |
| Topcon Healthcare, INC. | $75.95 | 2024 | |
| Kala Pharmaceuticals, INC. | $17.77 | 2021 | |
| Oyster Point Pharma, INC. | $15.49 | 2024 | Tyrvaya |
| Biotissue Holdings INC. | $13.67 | 2021 | |
| Visioneering Technologies, INC. | $9.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.